Recent News

• 09.17.2025 - Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
• 09.10.2025 - Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
• 09.09.2025 - Morgan Stanley Global Healthcare Conference
• 09.04.2025 - Wells Fargo Healthcare Conference
• 09.03.2025 - Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
• 09.03.2025 - Cantor Global Healthcare Conference
• 08.27.2025 - Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 08.25.2025 - Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
• 08.19.2025 - Incyte to Present at Upcoming Investor Conferences

Recent Filings

• 09.16.2025 - 144 Report of proposed sale of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2025 - 144 Report of proposed sale of securities
• 08.27.2025 - 3 Initial statement of beneficial ownership of securities
• 08.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.15.2025 - 144 Report of proposed sale of securities
• 08.13.2025 - 144 Report of proposed sale of securities
• 08.12.2025 - 144 Report of proposed sale of securities
• 08.07.2025 - 8-K Current report